Loading organizations...
Abyrx has raised $10.0M across 1 funding round.
Key people at Abyrx.
Abyrx has raised $10.0M in total across 1 funding round.
Founded in 2013 by John Pacifico, Abyrx is an Irvington, New York based medical technology company that develops, manufactures, and commercializes advanced biomaterials and therapeutic devices for surgical procedures. The firm focuses on biosurgical solutions, including bone hemostats and settable adhesives used by orthopedic and neurological surgeons, utilizing a proprietary materials science platform protected by over eighty patents. Operating with about 28 employees, the privately held enterprise generates an estimated five to seven million dollars in annual revenue through its direct sales model. Backed by lead investor Canaan Partners, the organization expanded its portfolio by acquiring assets from Orthocon alongside polymer technology from Bezwada Biomedical. The company recently received additional FDA clearances for its Montage bone putty and partnered with distribution network Kairuku to launch MedEdge Holdings in a transaction valued at 450 million dollars.
Abyrx has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series U in December 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2016 | $10M Series U | — | Canaan Partners, Domain Associates | Announced |
Abyrx has raised $10.0M in total across 1 funding round.
Abyrx's investors include Canaan Partners, Domain Associates.
Key people at Abyrx.
# Abyrx: Advanced Biomaterials for Surgical Innovation
Abyrx is a surgical therapeutic devices company, not a traditional technology firm, though it leverages advanced materials science as its core competency[1][3]. Founded in 2013, the company develops, manufactures, and distributes hemostatic and settable bone putties—resorbable biomaterials designed for use during surgical procedures across orthopedic, trauma, spine, sports medicine, cranial, maxillofacial, and cardiothoracic applications[2][3].
The company solves a critical surgical problem: managing bone defects and bleeding during procedures. Its flagship product, MONTAGE, is the first FDA-approved settable bone putty for use on the sternum and represents a shift toward cohesive, water-soluble, resorbable solutions that surgeons can apply with ease[1]. With products deployed across more than 1,000 U.S. hospitals and approaching 450,000 cumulative uses, Abyrx has achieved meaningful clinical adoption and over $100 million in cumulative revenues[1].
Abyrx was established in 2013 through the acquisition of the HEMASORB Resorbable Hemostatic Bone Putty portfolio and the rights to develop Bezwada Biomedical's polymer technology for bone applications[3][4]. This founding strategy—acquiring an existing product line while securing access to proprietary polymer chemistry—positioned the company to rapidly commercialize advanced biomaterials rather than starting from basic research.
Founder and CEO John J. Pacifico has guided the company's evolution from a single-product portfolio into a multi-indication platform. The company's early traction came through FDA clearances for MONTAGE across multiple surgical applications, with the September 2023 approval for cardiac surgery (sternum use) representing a significant validation of the technology's versatility[1].
Abyrx operates at the intersection of biomaterials innovation and surgical device commercialization—a sector experiencing accelerating consolidation and investment as healthcare systems demand products that improve outcomes while reducing operative time and complexity.
The company benefits from several macro trends: aging populations requiring more surgical interventions, surgeon preference for resorbable solutions over permanent implants, and healthcare economics favoring products that reduce complications and hospital stays. Its focus on hemostasis and bone regeneration addresses two of surgery's most persistent challenges, positioning it within a growing bone wax and bone putty market projected to reach $73 million globally by 2033[2].
Abyrx's success also reflects a broader shift in medtech toward materials science-driven innovation—companies that own proprietary chemistry and manufacturing processes command pricing power and switching costs that pure device assemblers cannot match.
Abyrx is well-positioned for continued growth as MONTAGE penetration deepens across its approved indications and as clinical evidence from randomized trials strengthens surgeon adoption in cardiac surgery—historically a high-value, high-stakes segment where proven safety and efficacy drive purchasing decisions.
The company's privately-held status (having raised $10 million in Series B funding) suggests either a path toward acquisition by a larger medtech player seeking to expand its surgical biomaterials portfolio, or potential for a later-stage funding round to support geographic expansion and new indication development[2]. Either trajectory would validate the core thesis: that surgeon-centric design combined with proprietary materials science creates defensible competitive advantages in surgical therapeutics.
